Glythera, a biotechnology company specializing in the development of next generation bio-therapeutics, including Antibody Drug Conjugates, through the application of its proprietary linker and stable glycan technologies PermaLink and PermaCarb, has appointed of Nigel Burns as non-executive director and Ian Evetts as commercial director. Glythera has recently validated data from their core technologies and the addition of Burns and Evetts coincides with the company’s expansion plan exploring new opportunities to provide essential support during the company’s growth plan.
Burns brings over 25 years experience in the biopharmaceuticals and biotechnology industry to Glythera. He has extensive experience leading product management and has held a series of leadership roles including, senior vice president of Cambridge Antibody Technology, non-executive director of Navion, chairman of Cell Medica, director and founder of Nascient and most recently, CEO and founder of SweetSpot Therapeutics. As non-executive director, Burns will support the development of Glythera’s technology and future business strategies, bringing new levels of focus and innovation to the company’s offerings.
Evetts joins Glythera with over 20 years experience in the pharmaceutical industry. He has a track record of senior strategic and operational roles including, managing director at Atebion BDS, strategic advisor at Bionure and business development and portfolio director at AstraZeneca. As commercial director of Glythera, he will provide strategic advice on developing the company’s technologies and therapies, a key growth area for Glythera.